about
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseasesSRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorderTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerAdverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic ReviewStructural basis for species specific inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): computational study and biological validationHydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1)Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometryKinase modulation of androgen receptor signaling: implications for prostate cancerInhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats.Role of 5α-reductase inhibitors in benign prostatic diseases.Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research.Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis.Targets to treat androgen excess in polycystic ovary syndrome.Finasteride Enhances the Generation of Human Myeloid-Derived Suppressor Cells by Up-Regulating the COX2/PGE2 PathwayVarious treatment options for benign prostatic hyperplasia: A current update.Is transforming growth factor-β signaling activated in human hypertrophied prostate treated by 5-alpha reductase inhibitor?Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implicationsCD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway.Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase.Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion.Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Targeting 5α-reductase for prostate cancer prevention and treatmentAnticancer steroids: linking natural and semi-synthetic compounds.Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia.The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.The strategies to control prostate cancer by chemoprevention approaches.Carbon-carbon double-bond reductases in nature.Potential targets in the discovery of new hair growth promoters for androgenic alopecia.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?Ethanol enhances neurosteroidogenesis in hippocampal pyramidal neurons by paradoxical NMDA receptor activation.Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.Synthesis and evaluation of some 17-acetamidoandrostane and N,N-dimethyl-7-deoxycholic amide derivatives as cytotoxic agents: structure/activity studies.First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent DiseasesAllelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.Activity landscape analysis of novel 5[Formula: see text]-reductase inhibitors.Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence.7-Aza-des-A-steroids with Antimicrobial and Cytotoxic Activity.
P2860
Q21285041-F5FD2B61-7C7F-4C75-B001-80A7A3C7FDB5Q24338882-757DDB9F-5219-4CC8-A7CB-1FCABB446DA5Q26750620-1182CED3-E231-44F7-9EF0-1DC2F072394EQ28069186-84114B0B-4E59-4A78-91F7-D3A99333C47EQ28476474-9687F829-79A7-4975-9360-03AC40D78713Q28478724-AC4C1C07-8D36-4464-9585-93D86EB9001EQ33463058-036BF0D4-AAE8-4AE5-AFFD-8E748FC53644Q33757289-2531AB4C-4A4D-4E5F-BF15-CFF7A13C1C1FQ34240687-80A2C1AD-8323-421D-A21B-EFF465144391Q34254296-6F2806BB-C17F-4BCE-AF21-DAA740099072Q34284547-EE869BD1-11E0-483C-9DBA-ABBA4D8AF3D4Q34313221-CE770DD4-1290-4624-87F0-BA3FB325F9C6Q35721207-A18D7B34-7790-41B2-8DA8-14A4BA03A3FCQ35835501-FD0C8916-CF26-47FC-A8F6-05750200AC0AQ36037921-5006A02F-A152-4BDC-9C5B-80FDE35E778FQ36181722-FAD636EB-B29D-4090-9411-8552661B8B8BQ37338238-AFDAB2B2-D956-4A31-9058-7078DE3E216DQ37639218-527A14D1-E794-4C4A-824E-F0ECE2009F1DQ37652222-8445F3F9-5F2C-423F-ADF6-F7958730841EQ37705997-7ADAA5B7-C766-4422-A864-DD61B310B551Q37720293-F27944BA-5515-41DF-BFD1-59857C6E33DCQ37790387-880E4DBD-EF68-4225-9C63-A8FA028E08E7Q37883012-C965217B-D499-42B9-8701-9B23DD96BA86Q38059807-FD49ED28-3CFC-4BAF-B9AF-52094ED54E83Q38105608-09246F6A-D51F-47DB-ADE6-77BAA3989C0BQ38111255-A34AE1C1-4808-4F58-922B-7489C2D4086BQ38175776-94C3FCC7-E82F-4D90-9705-64D2AE8CA8D2Q38205904-1975BA11-F3EF-4EDE-86DB-2AD69E90ECE5Q38215774-F358FABB-0B74-4FE4-AEE2-4EE635C40A29Q38571198-FFAEE57C-DE47-4BFB-B8AB-34DBAAF3DC02Q38571540-9DBA1B00-5BCA-4552-A1EE-1D683C227972Q38620751-260A1597-B473-4235-A3B3-FAFFFB451446Q38845916-70B1420E-2760-4FF6-956C-C1E5A017F3FDQ38883820-688CA61B-2376-4E5D-8F9D-A5187C40DE0FQ39134559-204BE0B0-C20C-4C47-B65D-DF2C684DB207Q39514041-4DDE301F-927D-408F-82EA-DBDE06182681Q39668407-B517DF9F-D61E-48EA-8CF4-9C9C5B41F03BQ40037633-45E6F613-627D-4774-96F7-A49CEE9AB0FDQ42182685-A97F9574-D73C-49F1-BC93-9B75DE7AB5ECQ43107706-C591659B-5E32-48EA-B192-F23B0E6EBD90
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
An overview on 5alpha-reductase inhibitors.
@ast
An overview on 5alpha-reductase inhibitors.
@en
type
label
An overview on 5alpha-reductase inhibitors.
@ast
An overview on 5alpha-reductase inhibitors.
@en
prefLabel
An overview on 5alpha-reductase inhibitors.
@ast
An overview on 5alpha-reductase inhibitors.
@en
P2093
P1433
P1476
An overview on 5alpha-reductase inhibitors.
@en
P2093
Abhilasha Verma
Manoj Kumar
Saurabh Aggarwal
Suresh Thareja
Tilak Raj Bhardwaj
P304
P356
10.1016/J.STEROIDS.2009.10.005
P577
2009-10-30T00:00:00Z